PHAR (Pharming Group) Additional Paid-In Capital : $489.0 Mil(As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pharming Group Additional Paid-In Capital?

Pharming Group's quarterly additional paid-in capital increased from Jun. 2024 ($486.9 Mil) to Sep. 2024 ($487.1 Mil) and increased from Sep. 2024 ($487.1 Mil) to Dec. 2024 ($489.0 Mil).

Pharming Group's annual additional paid-in capital increased from Dec. 2022 ($462.3 Mil) to Dec. 2023 ($478.4 Mil) and increased from Dec. 2023 ($478.4 Mil) to Dec. 2024 ($489.0 Mil).

Pharming Group Additional Paid-In Capital Historical Data

The historical data trend for Pharming Group's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Additional Paid-In Capital Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

447.13

455.25

462.30

478.43

488.99

Pharming Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial															478.43	479.66	486.85	487.08	488.99

Pharming Group Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Pharming Group Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Pharming Group's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

PHGUF:USA PHARM:Netherlands 0QCO:UK PHG:Germany PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.